The University of North Carolina at Chapel Hill has received a seven-year, more than $40 million award from the National Institutes of Health for a clinical trials unit that will implement the scientific agendas of five NIH networks devoted to HIV/AIDS treatment, prevention, and cure research.
UNC has had a continuously funded AIDS Clinical Trials Unit since 1987. The latest competitive funding renewal consolidates HIV clinical research operations in North Carolina, Malawi, and Zambia into a Global HIV Prevention and Treatment Clinical Trials Unit (UNC Global CTU). The UNC Global CTU will receive approximately $5.5 million in the first year to continue and develop studies addressing the prevention, treatment, and cure of HIV infection.
"Researchers at Carolina have been at the forefront of the AIDS epidemic from day one," said Marschall Runge, MD, PhD, executive dean of the UNC School of Medicine. "This award recognizes the scientific leadership and global reach of the UNC HIV/AIDS enterprise."
UNC is home to a top-10 ranked HIV/AIDS program, involving dozens of researchers from laboratory scientists and clinicians to epidemiologists and policy experts. Between 2008 and 2012, the university received approximately $430 million in external research funding for HIV. The landmark study HPTN 052named "Breakthrough of the Year" in 2011was spearheaded by UNC researchers. It showed that HIV treatment prevents transmission of the virus. UNC is also home to one of the largest HIV cure initiatives in the world.
The new grant provides funding through 2021 for five clinical research sites that make up the UNC Global CTU: Chapel Hill, Raleigh, and Greensboro, N.C.; Lilongwe, Malawi; and Lusaka, Zambia. The Southeastern United States and sub-Saharan Africa represent some of the most severely affected populations in the United States and worldwide.
The UNC Global CTU will lead clinical research that addresses treatment of HIV
|Contact: Lisa Chensvold|
University of North Carolina Health Care